Last update 05 Oct 2025

Jemincare Therapeutics Corp.

Subsidiary Company|2018|New Jersey, United States|
www.jemincare.com

Overview

Tags

Neoplasms
Respiratory Diseases
Infectious Diseases
Small molecule drug
Herbal medicine
Monoclonal antibody

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Nervous System Diseases1
Neoplasms1
Infectious Diseases1
Endocrinology and Metabolic Disease1
Top 5 Drug TypeCount
Small molecule drug2
Herbal medicine1
Monoclonal antibody1
Top 5 TargetCount
SARS-CoV-2 S protein1
SMO(Smoothened receptor)1
NHE3(Sodium/hydrogen exchanger 3)1

Related

4
Drugs associated with Jemincare Therapeutics Corp.
Sonidegib Phosphate
Target
SMO
Mechanism
SMO antagonists
Active Org.
Novartis Pharmaceuticals Corp.Novartis Pharmaceuticals Corp. [+5]
Originator Org.
Novartis Pharma AG
Active Indication
Metastatic basal cell carcinoma [+17]
Inactive Indication
Acute Lymphoblastic Leukemia [+46]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
United States
First Approval Date24 Jul 2015
JinShuiBao
Target-
Mechanism-
Active Org.
Jemincare Therapeutics Corp.
Originator Org.
Jemincare Therapeutics Corp.
Active Indication
Chronic Kidney Diseases
Inactive Indication-
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
China
First Approval Date01 Jan 1989
JMB-2002
Target
SARS-CoV-2 S protein
Mechanism
SARS-CoV-2 S protein inhibitors
Active Org.
Jemincare Therapeutics Corp.
Originator Org.
Jemincare Therapeutics Corp.
Active Indication
COVID-19
Inactive Indication-
Drug Highest PhasePhase 2
First Approval Ctry. / Loc.-
First Approval Date-
3
Clinical Trials associated with Jemincare Therapeutics Corp.
NCT05821595
/ Unknown statusPhase 1
A Phase I, Multi-center, Open-label Study With Dose-escalation and Multiple Expansion Cohorts to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of JYB1907 in Subjects With Advanced Solid Tumors
NCT05907382
/ RecruitingPhase 1
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JMKX003002 in Single and Multiple Ascending Dose Randomized，Doubled-blind Phase 1 Study in Healthy Subjects
NCT04349683
/ Unknown statusPhase 4
Efficacy and Safety of Jinshuibao for Patients With Chronic Kidney Disease Due to Glomerulonephritis：A Multicenter Randomized Controlled Clinical Trial
100 Clinical Results associated with Jemincare Therapeutics Corp.
Login to view more data
0 Patents (Medical) associated with Jemincare Therapeutics Corp.
Login to view more data
100 Deals associated with Jemincare Therapeutics Corp.
Login to view more data
100 Translational Medicine associated with Jemincare Therapeutics Corp.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 09 Oct 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Phase 1
1
1
Phase 2
Approved
2
1
Other
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
Sonidegib Phosphate
 ( SMO )		Basal Cell Carcinoma
More
Approved
JinShuiBao
Chronic Kidney Diseases
More
Approved
JMB-2002
 ( SARS-CoV-2 S protein )		COVID-19
More
Phase 2
JYB-1907
 ( GARP/TGFβ1 )		Advanced Malignant Solid Neoplasm
More
Pending
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free